MARKET

INVA

INVA

Innoviva
NASDAQ
21.25
+0.29
+1.38%
After Hours: 21.25 0 0.00% 19:34 08/18 EDT
OPEN
21.24
PREV CLOSE
20.96
HIGH
21.46
LOW
21.21
VOLUME
628.82K
TURNOVER
--
52 WEEK HIGH
25.15
52 WEEK LOW
16.52
MARKET CAP
1.54B
P/E (TTM)
5.12
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INVA last week (0810-0814)?
Weekly Report · 1d ago
Innoviva management to meet virtually with Cantor Fitzgerald
TipRanks · 1d ago
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA)
Simply Wall St · 2d ago
IHF: Healthcare Dashboard For August
Seeking Alpha · 2d ago
Is Innoviva (INVA) A Bargain After Revenue Grew But Earnings Turned To Loss?
Simply Wall St · 3d ago
Weekly Report: what happened at INVA last week (0803-0807)?
Weekly Report · 08/10 10:19
Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA?
Simply Wall St · 08/08 15:21
Innoviva Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 08/07 12:47
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.